AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $391.50 billion. The enterprise value is $455.02 billion.
| Market Cap | 391.50B |
| Enterprise Value | 455.02B |
Important Dates
The next estimated earnings date is Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | Apr 15, 2026 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.82% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 109.15 and the forward PE ratio is 14.84. AbbVie's PEG ratio is 0.96.
| PE Ratio | 109.15 |
| Forward PE | 14.84 |
| PS Ratio | 6.23 |
| Forward PS | 5.76 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.59 |
| P/OCF Ratio | 18.45 |
| PEG Ratio | 0.96 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.21, with an EV/FCF ratio of 22.77.
| EV / Earnings | 126.57 |
| EV / Sales | 7.24 |
| EV / EBITDA | 15.21 |
| EV / EBIT | 20.80 |
| EV / FCF | 22.77 |
Financial Position
The company has a current ratio of 0.80
| Current Ratio | 0.80 |
| Quick Ratio | 0.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.41 |
| Debt / FCF | 3.65 |
| Interest Coverage | 7.52 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 10.03% |
| Return on Invested Capital (ROIC) | 22.83% |
| Return on Capital Employed (ROCE) | 23.19% |
| Weighted Average Cost of Capital (WACC) | 5.40% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $63,070 |
| Employee Count | 57,000 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 3.67 |
Taxes
In the past 12 months, AbbVie has paid $2.33 billion in taxes.
| Income Tax | 2.33B |
| Effective Tax Rate | 39.06% |
Stock Price Statistics
The stock price has increased by +15.97% in the last 52 weeks. The beta is 0.31, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +15.97% |
| 50-Day Moving Average | 211.06 |
| 200-Day Moving Average | 220.42 |
| Relative Strength Index (RSI) | 55.51 |
| Average Volume (20 Days) | 5,078,517 |
Short Selling Information
The latest short interest is 23.16 million, so 1.31% of the outstanding shares have been sold short.
| Short Interest | 23.16M |
| Short Previous Month | 20.91M |
| Short % of Shares Out | 1.31% |
| Short % of Float | 1.31% |
| Short Ratio (days to cover) | 3.88 |
Income Statement
In the last 12 months, AbbVie had revenue of $62.82 billion and earned $3.60 billion in profits. Earnings per share was $2.03.
| Revenue | 62.82B |
| Gross Profit | 45.25B |
| Operating Income | 21.88B |
| Pretax Income | 5.98B |
| Net Income | 3.60B |
| EBITDA | 29.92B |
| EBIT | 21.88B |
| Earnings Per Share (EPS) | $2.03 |
Balance Sheet
The company has $9.39 billion in cash and $72.91 billion in debt, with a net cash position of -$63.52 billion or -$35.95 per share.
| Cash & Cash Equivalents | 9.39B |
| Total Debt | 72.91B |
| Net Cash | -63.52B |
| Net Cash Per Share | -$35.95 |
| Equity (Book Value) | -6.61B |
| Book Value Per Share | -3.77 |
| Working Capital | -8.57B |
Cash Flow
In the last 12 months, operating cash flow was $21.22 billion and capital expenditures -$1.24 billion, giving a free cash flow of $19.98 billion.
| Operating Cash Flow | 21.22B |
| Capital Expenditures | -1.24B |
| Depreciation & Amortization | 8.04B |
| Net Borrowing | 2.63B |
| Free Cash Flow | 19.98B |
| FCF Per Share | $11.31 |
Margins
Gross margin is 72.03%, with operating and profit margins of 34.83% and 5.79%.
| Gross Margin | 72.03% |
| Operating Margin | 34.83% |
| Pretax Margin | 9.51% |
| Profit Margin | 5.79% |
| EBITDA Margin | 47.62% |
| EBIT Margin | 34.83% |
| FCF Margin | 31.81% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 3.12%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 3.12% |
| Dividend Growth (YoY) | 5.64% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 332.01% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 3.08% |
| Earnings Yield | 0.92% |
| FCF Yield | 5.10% |
Analyst Forecast
The average price target for AbbVie is $253.55, which is 14.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $253.55 |
| Price Target Difference | 14.42% |
| Analyst Consensus | Buy |
| Analyst Count | 32 |
| Revenue Growth Forecast (3Y) | 8.48% |
| EPS Growth Forecast (3Y) | 21.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.29 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | 8 |